Navigation Links
Novel mechanism for control of gene expression revealed
Date:3/4/2011

(Boston) Dr. David Levin, Professor of Molecular & Cell Biology at Boston University Henry M. Goldman School of Dental Medicine and Professor of Microbiology at Boston University School of Medicine discovered recently a novel, evolutionarily conserved mechanism for the regulation of gene expression. The study describing this work titled, "Mpk1 MAPK Association with the Paf1 Complex Blocks Sen1-Mediated Premature Transcription Termination," appears in the March 4 issue of Cell.

Normal cell growth, embryonic development, and responses to stress, require proper spatial and temporal control of gene expression. Studies on control of transcription (RNA biosynthesis) are typically centered on understanding how the RNA polymerase is recruited to the promoter, the control region of a gene. However, new work from Levin and postdoctoral fellow, Ki-Young Kim, has revealed the existence of a second level of control in a yeast model system.

They found that genes expressed solely under certain stress conditions are normally maintained in a silent state by a process called transcriptional attenuation. In attenuation, the RNA polymerase initiates transcription of the gene, but its progress is terminated prematurely by a termination complex that binds to the polymerase. Attenuation occurs commonly in bacteria, but was not previously known to operate in eukaryotic cells (those with a nucleus).

"In response to an inducing stress signal, attenuation must be overcome so that a target gene can be expressed," said Levin. "The way that works in this instance is that an activating transcription factor, called Mpk1, serves double dutyit is first responsible for recruitment of the RNA polymerase to the promoter, but Mpk1 then binds to the transcribing polymerase to block association of the termination complex."

Mutations in a human protein, called Senataxin, which is related to a component of the yeast termination complex, are responsible for causing juvenile-onset forms of ALS and ataxia, two neuromuscular degenerative diseases.

In their newest research, Levin and Kim show that the discovered attenuation mechanism is evolutionarily conserved in humans. "The findings of this research have broad implications that translate to human cells," said Levin. "We know that when the key yeast proteins are replaced by their human counterparts, they are able to engage in the same interactions to exert control over attenuation."

Levin believes that attenuation is actually a widespread phenomenon. "Approximately 10% of yeast genes appear to be under attenuation control, which suggests that it may also be common in humans," said Levin. "This opens the door to the possibility of new approaches to therapeutic gene silencing, now that we know transcriptional attenuation operates in eukaryotic cells and that it's a regulated process."


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Novel methods for improved breast cancer survival
2. Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
3. Novel surgery removes rare tumor, rebuilds trachea
4. Researchers reveal function of novel molecule that underlies human deafness
5. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
6. UCI researchers find novel memory-enhancing mechanism in brain
7. Novel imaging technique may reduce lymphedema in breast cancer patients
8. New standards of care and novel treatment options for several forms of lymphoma unveiled
9. Novel genetic mutation that causes the most common form of eye cancer discovered
10. Quebec City researchers pave the way for novel treatment of pulmonary hypertension
11. Eat safer: Novel approach detects unknown food pathogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Visiting ... the C. R. Bard Foundation, Inc. to support the music therapy ... service available through the nonprofit home care agency. Using evidence-based methods, professionally trained ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is ... product of her research center at Bio-Logic Aqua Research® Water Life Science®, has ... greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in Houston, is pleased to announce their expansion to the Midwest with the ... directors Alysse Hollis and Ronald Bell, and of counsels, John Peck and Robert ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Did you know that PhRMA member companies invested $65.5 billion ... on brand medicines, generics and the supply chain account for 14 ... half of this (7 percent)? Or that the United ... capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry ...
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
Breaking Medicine Technology: